Novartis gains U.S. approval for dairy cattle vaccine

 Resize text         Printer-friendly version of this article Printer-friendly version of this article
Swiss drugs group Novartis said Tuesday it’s recently acquired U.S. vaccine firm ImmTech Biologics has won a
conditional license in the United States to use Treponema Bacterin, a vaccine designed to prevent digital dermatitis — hairy heel warts — in dairy cattle.

“Digital dermatitis is a costly disease for dairy producers and Treponema Bacterin is the only immunological solution available,” said Mark Hodgson, President of Novartis Animal Vaccines Inc., in a statement.
“It allows dairy producers to reduce environmental, worker safety and milk-quality issues associated with chemical and antibiotic management of heel warts,” he added.


Comments (0) Leave a comment 

e-Mail (required)


characters left

Biotal Forage Inoculants

"Biotal offers a range of forage inoculants proven to help win the battle to preserve feed quality and value. Call ... Read More

View all Products in this segment

View All Buyers Guides

Feedback Form
Leads to Insight